September 30, 2020 – Over the past few months, numerous healthcare organizations have turned to executive search firms to find new chief medical officers. And in the era of COVID-19 we can expect this to be another burgeoning area for executive search firms. Recently, life sciences-focused search firm Slone Partners placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle, WA.
“As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development and regulatory strategy,” said Tara Kochis-Stach, president of Slone Partners. “He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs.”
“Mike’s extensive experience across all facets of clinical drug, device and diagnostic test development, including oversight of a vast array of FDA approvals and successful clinical trials, will be invaluable to Lumen as we look to advance and expand our clinical pipeline,” said Brian Finrow, Lumen’s co-founder and CEO. “We found our way to Mike after an exhaustive, nationwide search, and his unique background of high-impact product developed experience in industry and deep theoretical founding from his time in academia stood out prominently.”
Dr. Spigarelli brings more than 30 years of experience in clinical product development, including trial design, implementation, data analysis and oversight to his new role. He is also an experienced practitioner in medical research and development, scientific research, and clinical leadership and education.
Dr. Spigarelli most recently served as vice president of medical affairs at Immucor Inc., where he helped develop and obtain FDA and global regulatory approval for numerous assays and reagents and led the company’s global clinical affairs and assay development teams. Prior to that, he partnered with numerous drug, device and diagnostic development companies on clinical trial design, site selection and regulatory strategy. Dr. Spigarelli formerly served in the academic environment, reaching the rank of professor of pediatrics, internal medicine and pharmaceutics and therapeutics and developing clinical trials offices to improve clinical research at several major universities.
Clinical-Stage Biopharmaceutical Company
Established in 2017, Lumen Bio is a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases. Lumen Bio’s clinical pipeline includes investigational biologics for traveler’s diarrhea, norovirus and C. difficile infection.
Slone Partners Recruits CEO for Mesa Biotech
The race is on to find a vaccine for COVID-19 – and along with it the pace is picking up to find top leadership talent at many of the nation’s leading life sciences, medical diagnostics and biotech companies. Here’s one of the latest searches just successfully completed.
As chief medical officer, Dr. Spigarelli will help advance Lumen Bio’s impressive clinical pipeline. “Lumen’s unique approach to drug development offers the potential to impact the treatment landscape for many diseases that currently lack effective treatments,” Dr. Spigarelli said. “I am overjoyed to build Lumen’s clinical development team and guide the development of these potential products into clinical trials, through the regulatory pathway, and on to the world market where they can start to positively impact patients’ lives.”
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C. and San Francisco. Recently, the firm was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
In May, Slone Partners placed Roger D. Klein as chief medical officer of OmniSeq. “Dr. Klein is a highly accomplished leader in the innovative fields of molecular pathology, oncology and precision medicine,” said Ms. Kochis-Stach, president of Slone Partners. “He will be a tremendously valuable addition to OmniSeq’s executive team.”
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media